Prophylaxis in hemophilia
Clin. biomed. res
; 43(1): 58-68, 2023.
Artigo
em Inglês
| LILACS
| ID: biblio-1435960
Biblioteca responsável:
BR18.1
ABSTRACT
Hemophilia is an inherited X-linked coagulopathy defined by a deficiency or abnormality in the clotting function of factor VIII (Hemophilia A) or factor IX (Hemophilia B). Prophylaxis the regular administration of therapeutic products to maintain hemostasis and prevent bleeding is the mainstream of treatment. Addressing the development and scientific evidence for administrating prophylaxis is the goal of this review. Prophylaxis is the therapeutic modality of choice for people with severe hemophilia, being considered, in principle, a lifelong treatment. It should have an early onset, ideally as a primary, or at least secondary. Even lifelong tertiary prophylaxis seems to offer benefit, although further studies are still lacking. Individualized strategies should lead to an optimization of the dilemma between better joint outcomes versus involved costs.
Assuntos
Texto completo:
Disponível
Coleções:
Bases de dados internacionais
Base de dados:
LILACS
Assunto principal:
Fator VIII
/
Hemofilia B
/
Hemofilia A
Limite:
Feminino
/
Humanos
/
Masculino
Idioma:
Inglês
Revista:
Clin. biomed. res
Assunto da revista:
Medicina
Ano de publicação:
2023
Tipo de documento:
Artigo
País de afiliação:
Brasil
Instituição/País de afiliação:
Hospital de Clínicas de Porto Alegre/BR
/
Universidade Estadual do Rio Grande do Sul/BR
/
Universidade Federal do Rio Grande do Sul/BR
/
Universidade de Caxias do Sul/BR